UNSPSC 51172180: Propiverine hydrochloride

This classification denotes an antispasmotic agent and antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DC4GZD10H3. European Medicines Agency schedules Propiverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04087MIG. Propiverine hydrochloride generally arises in the molecular formula C23H29NO3.CLH. The term 'propiverine hydrochloride' is a Japanese Accepted Name designation.

Most nations, for tariff and trade purposes, schedule propiverine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PROPIVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCOC(C1CCCCC1)(C2CCCCC2)C(=O)OC3CCN(CC3)C.CL.

UNSPSC 51172180 Propiverine hydrochloride, a Commodity code, shows minimal alignment with recent state and local procurement activity. The single identified recent opportunity—Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services—does not procure the pharmaceutical product named in the code. Instead, the Collin County solicitation covers lab staffing, specimen collection site operations, drug screening and confirmation testing (immunoassay with LC/MS/MS or GC/MS confirmation), result reporting, and alternative testing methodologies including oral fluid and hair analysis. The scope is narrowly focused on criminal-justice drug-testing services rather than pharmaceutical procurement. Propiverine hydrochloride is an anticholinergic agent used to treat urinary urgency; its presence in the UNSPSC taxonomy does not reflect current state and local buying patterns in this code.

The Collin County RFP (due July 23, 2026, with anticipated award August 10, 2026) represents testing demand of approximately 25,031 annual tests across five-panel and six-panel screens at an estimated contract value of $600,000 over two years, with up to three optional one-year renewal periods. The contract runs through September 1, 2026, and pricing is submitted per test with no additional surcharges permitted. Vendors must maintain lab certification from SAMHSA, Texas DPS, or CAP. This single Texas-based opportunity does not establish meaningful geographic spread or a pattern of repeated buying under the code. No other state or local jurisdictions appear in the recent-opportunities record. Firms evaluating this code should treat it as dormant for pharmaceutical procurement purposes; activity appears limited to an incidental mislabeling of a drug-testing services solicitation.